Heart Researchers Unpack Neutral Findings From ZEUS, an Anti-Inflammatory Clinical Trial

Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD

(MedPage Today) -- Despite lowering inflammatory markers, treatment with the monoclonal antibody ziltivekimab did not reduce cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and...

Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial

Like cholesterol, inflammation causally contributes to the risk of cardiovascular disease, but findings from the clinical trial ZEUS indicate that the road to targeting inflammation may be less straightforward than once thought. ZEUS, a global phase 3 clinical trial led by Mass General Brigham researcher Paul Ridker, M.D., tested a drug that targets interleukin-6 (IL-6), a downstream inflammatory molecule. IL-6 inhibitors are commonly used to tr…

Researchers say inflammation as a treatment target still important despite neutral results of ZEUS trial

Open the article to view the coverage from NewMediaWire

ZEUS Trial: Anti-Inflammatory Drug Ziltivekimab Fails to Reduce Cardiovascular Events in High-Risk Patients

The ZEUS trial found that ziltivekimab, an interleukin-6 inhibitor, did not significantly reduce major cardiovascular events despite lowering inflammation markers in patients with atherosclerotic cardiovascular disease and chronic kidney disease, highlighting the need for earlier intervention and continued focus on inflammation as a treatment target. The post ZEUS Trial: Anti-Inflammatory Drug Ziltivekimab Fails to Reduce Cardiovascular Events i…